Skip to main content
Log in

Recommendations for the reporting of fallopian tube neoplasms

  • Recommendation
  • Published:
Virchows Archiv Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. AJCC (2002) AJCC cancer staging manual, 6th edn. Lippincott-Raven, pp 285–290

  2. Alvarado-Cabrero I, Young RH, Vamvakas EC, Scully RE (1999) Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors. Gynecol Oncol 72:367–379

    Article  PubMed  CAS  Google Scholar 

  3. Benda JA, Zaino R (1994) GOG pathology manual. Gynecologic Oncology Group, Buffalo, NY

  4. Cheung AN, Young RH, Scully RE (1994) Pseudocarcinomatous hyperplasia of the fallopian tube associated with salpingitis. A report of 14 cases. Am J Surg Pathol 18:1125–1130

    Article  PubMed  CAS  Google Scholar 

  5. Colgan TJ, Murphy J, Cole DE et al (2001) Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 25:1283–1289

    Article  PubMed  CAS  Google Scholar 

  6. Medeiros F, Muto MG, Lee Y et al (2006) The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30:230–231

    Article  PubMed  Google Scholar 

  7. Narod SA, Sun P, Ghadirian P et al (2001) Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 357:1467–1470

    Article  PubMed  CAS  Google Scholar 

  8. Powell CB Kenley E, Chen LM et al (2005) Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 23:127–132

    PubMed  Google Scholar 

  9. Rosenblatt KA, Thomas DB (1996) Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization collaborative study of neoplasia and steroid contraceptives. Cancer Epidemiol Biomark Prev 5:933–935

    CAS  Google Scholar 

  10. World Health Organization Classification of Tumours (2003) Pathology & genetics. Tumours of the breast and female genital organs. IARC Press, Lyon

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Teri A. Longacre.

AppendixAssociation of Directors of Anatomic and Surgical Pathology Final Anatomic Diagnosis Checklist

AppendixAssociation of Directors of Anatomic and Surgical Pathology Final Anatomic Diagnosis Checklist

Fallopian tube neoplasms

Version 1.0 (3-06)

Accession no.:

Part no(s).:

Date:

Patient name:

Organ:

Procedure:

 

Fallopian tube (specify laterality)

Salpingectomy

 

Fallopian tube and ovary (specify laterality)

Salpingo-oophorectomy

 

Uterus, cervix, bilateral ovaries, and fallopian tubes

Hysterectomy and bilateral salpingo-oophorectomy

 

Uterus, cervix, bilateral ovaries, bilateral fallopian tubes, and lymph nodes (specify site)

Hysterectomy, bilateral salpingo-oophorectomy, and lymphadenectomy

 

Uterus, cervix, bilateral ovaries, bilateral fallopian tubes, omentum, and lymph nodes (specify site)

Hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and lymphadenectomy

 

Uterus, cervix, bilateral ovaries, bilateral tubes, omentum, peritoneal biopsies, and lymph nodes (specify sites)

Hysterectomy, bilateral salpingo-oophorectomy, omentectomy, peritoneal biopsies, and lymphadenectomy

 

Others

Primary tumor diagnosis [10]:Required

 Serous tumor of low malignant potential

 Endometrioid tumor of low malignant potential

 Serous adenocarcinoma

 Endometrioid adenocarcinoma

 Mucinous adenocarcinoma

 Clear cell adenocarcinoma

 Transitional cell carcinoma

 Squamous cell carcinoma

 Mixed (each component should comprise 10% or more of the tumor)

 Undifferentiated carcinoma

 Metastatic carcinoma

 Others (specify)

Tumor site:Required

 Isthmus

 Ampulla

 Infundibulum (fimbria)

Note: Fimbrial carcinomas may have a poorer prognosis due to tumor cell shedding directly to the peritoneum even in the absence of invasion [2].

Tumor grade:Required

Note: Because a universal or standard grading scheme for fallopian tube carcinoma has not been established, the grading scheme must be specified. The GOG arbitrarily uses a single grading system for endometrium, ovary, and fallopian tube, which serves to maintain consistency in diagnosis and classification. Other grading schemes have also been proposed and we do not endorse one system over another. However, regardless of the grading system used, the ADASP strongly endorses a single uniform grading scheme for ovarian, fallopian tube, and extraovarian carcinoma whenever possible. The GOG system is provided below [3]. Other systems may also be used so long as this is clearly stated in the report.

Grade cannot be assessed: specify reason

Low malignant potential (borderline)

G1 (well-differentiated): 5% or less of a nonsquamous or nonmorular solid growth pattern

G2 (moderately differentiated): 6–50% of a nonsquamous or nonmorular solid growth pattern

G3 (poorly differentiated): >50% of a nonsquamous or nonmorular solid growth pattern

G4 (undifferentiated)

Notable nuclear atypia, inappropriate for the architectural grade, raises the grade of a grade 1 or grade 2 tumor by one level. Clear cell carcinomas are generally not graded.

Extent of tumor [1]:Required

 Tumor is

Limited to tubal mucosa or

Confined to one fallopian tube with invasion of the lamina propria only, no positive pelvic washings or

Confined to one fallopian tube with invasion of the muscularis propria only, no positive pelvic washings or

Confined to both fallopian tubes with invasion of the lamina propria only, no positive pelvic washings or

Confined to both fallopian tubes with invasion of the muscularis propria only, no positive pelvic washings or

Confined to one or both tubes with peritoneal surface involvement and/or positive pelvic washings

Present in one or both tubes with pelvic extension (specify whether extension involves uterusa and/or ovariesa or other pelvic structures) or

Present in one or both tubes with peritoneal implants outside the pelvis and/or regional lymph node metastasis (specify microscopic, macroscopic but less than 2.0 cm, greater than 2.0 cm, and/or regional lymph node metastasis) or

Present in distant metastasis including malignant cells in pleural fluid or parenchymal liver metastasis

   aInvolvement of ovaries and/or endometrium

Note: Current AJCC and FIGO staging do not distinguish between invasion into lamina propria only and invasion into muscularis propria. However, because substaging is based on depth of invasion in other hollow organs with muscle walls, such as gastrointestinal tract and urinary bladder, the ADASP recommends a similar staging standard for fallopian tube carcinoma. Different survival rates depending upon the depth of invasion have been reported [2].

Lymphovascular space invasion:Optional

 Absent

 Present

Associated features:Optional

 Endosalpingiosis

 Endometriosis

 Others

Other findings:Optional

Ancillary studies:Required (if performed)

pTNM/FIGO stage [1]:Required

Primary tumor:b

TNM

FIGO

 

pTX

 

Primary tumor cannot be assessed

pT0

 

No evidence of primary tumor

pTis

0

Carcinoma in situ (tumor limited to tubal mucosa)

pT1

I

Tumor limited to the fallopian tube(s)

pT1a

IA

Tumor limited to one fallopian tube, without penetration of serosal surface, no malignant ascites or peritoneal washings

pT1b

IB

Tumor limited to both fallopian tubes, without penetration of serosal surface, no malignant ascites or peritoneal washings

pT1c

IC

Tumor limited to one or both fallopian tubes with extension onto or through the serosal surface, or with malignant cells in ascites or peritoneal washings

pT2

II

Tumor involves one or both fallopian tubes with pelvic extension

pT2a

IIA

Extension and/or metastasis to the uterus and/or ovaries

pT2b

IIB

Extension to other pelvic structures

pT2c

IIC

Pelvic extension with malignant cells in ascites or peritoneal washings

pT3

III

Tumor involves one or both fallopian tubes with peritoneal implants outside the pelvisc

pT3a

IIIA

Microscopic peritoneal metastasis outside the pelvis

pT3b

IIIB

Macroscopic peritoneal metastasis outside the pelvis 2.0 cm or less in greatest dimension

pT3c

IIIC

Peritoneal metastasis greater than 2.0 cm in greatest dimension

Regional lymph nodes:

pNX

 

Regional lymph nodes cannot be assessed

pN0

 

No regional lymph node metastases

pN1

IIIC

Regional lymph node metastases

Distant metastases:

pMX

 

Presence of distant metastases cannot be assessed

pM0

 

No distant metastases

pM1

IV

Distant metastases

bIn the absence of other specific staging instructions, it is recommended that all other primary malignancies of the fallopian tube be staged accordingly (e.g., carcinosarcoma)

cLiver capsule metastasis is T3; liver parenchymal metastasis is M1.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Longacre, T.A., Oliva, E., Soslow, R.A. et al. Recommendations for the reporting of fallopian tube neoplasms. Virchows Arch 450, 25–29 (2007). https://doi.org/10.1007/s00428-006-0303-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-006-0303-5

Keywords